A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis

Phase 2 Not yet recruiting 252 enrolled Arrowhead Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the safety and efficacy of ARO-INHBE in adults with suspected metabolic dysfunction-associated steatohepatitis (MASH).

Timeline

Start: 2026-09
Primary completion: 2029-10
Completion: 2029-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARO-INHBE	Unknown	—	Subcutaneous

A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis

Summary

Timeline

Drugs

Indications